Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2021

Open Access 01-12-2021 | Dyslipidemia | Research

Prevalence and trends of coronary artery disease risk factors and their effect on age of diagnosis in patients with established coronary artery disease: Tehran Heart Center (2005–2015)

Authors: Kaveh Hosseini, Seyedeh Hamideh Mortazavi, Saeed Sadeghian, Aryan Ayati, Mahdi Nalini, Arya Aminorroaya, Hamed Tavolinejad, Mojtaba Salarifar, Hamidreza Pourhosseini, Afsaneh Aein, Arash Jalali, Ali Bozorgi, Mehdi Mehrani, Farin Kamangar

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Login to get access

Abstract

Background

Coronary artery disease (CAD) is a universal public health challenge, more prominently so in the low- and middle-income countries. In this study, we aimed to determine prevalence and trends of CAD risk factors in patients with documented CAD and to determine their effects on the age of CAD diagnosis.

Materials and methods

We conducted a registry-based, serial cross-sectional study using the coronary angiography data bank of the Tehran Heart Center. Adult patients who had obstructive (> 50% stenosis) CAD were included in the study. The prevalence and 11-year trends of conventional CAD risk factors were analyzed by sex and age, and their adjusted effects on the age of CAD diagnosis were calculated.

Results

From January 2005 to December 2015, data for 90,094 patients were included in this analysis. A total of 61,684 (68.5%) were men and 28,410 (31.5%) were women. Men were younger at diagnosis than women, with a mean age of 60.1 in men and 63.2 in women (p < 0.001), and had fewer risk factors at the time of diagnosis. Mean age at diagnosis had an overall increasing trend during the study period. Increasing trend was seen in body-mass index, hypertension prevalence, diabetes mellitus. All lipid profile components (total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol) decreased over time. Of particular interest, opium consumption was associated with 2.2 year earlier age of CAD diagnosis.

Conclusion

The major results of this study (lower age of CAD diagnosis in men, lower age of diagnosis associated with most risk factors, and lower prevalence of serum lipids over time) were expected. A prominent finding of this study is confirming opium use was associated with a much younger age of CAD onset, even after adjusting for all other risk factors. In addition to recommendations for control of the traditional risk factors, spreading information about the potential adverse effect of opium use, which has only recently been associated with higher risk of CAD, may be necessary.
Literature
1.
go back to reference Burt VL, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305–13.CrossRef Burt VL, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305–13.CrossRef
2.
go back to reference Asgari S, et al. The burden of statin therapy based on ACC/AHA and NCEP ATP-III guidelines: an Iranian survey of non-communicable diseases risk factors. Sci Rep. 2018;8(1):1–7.CrossRef Asgari S, et al. The burden of statin therapy based on ACC/AHA and NCEP ATP-III guidelines: an Iranian survey of non-communicable diseases risk factors. Sci Rep. 2018;8(1):1–7.CrossRef
3.
go back to reference Dai H, et al. Global, regional, and national burden of ischemic heart disease and its attributable risk factors, 1990–2017: results from the global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2020. Dai H, et al. Global, regional, and national burden of ischemic heart disease and its attributable risk factors, 1990–2017: results from the global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2020.
4.
go back to reference Roth GA, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.CrossRef Roth GA, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.CrossRef
5.
go back to reference Aminorroaya A, et al. Global, regional, and national quality of care of ischaemic heart disease from 1990 to 2017: a systematic analysis for the global burden of disease study 2017. Eur J Prevent Cardiol. 2021. Aminorroaya A, et al. Global, regional, and national quality of care of ischaemic heart disease from 1990 to 2017: a systematic analysis for the global burden of disease study 2017. Eur J Prevent Cardiol. 2021.
6.
go back to reference Elagizi A, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2018;61(2):142–50.CrossRef Elagizi A, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2018;61(2):142–50.CrossRef
7.
go back to reference Sadeghi M, et al. Modeling the burden of cardiovascular diseases in Iran from 2005 to 2025: the impact of demographic changes. Iran J Public Health. 2017;46(4):506.PubMedPubMedCentral Sadeghi M, et al. Modeling the burden of cardiovascular diseases in Iran from 2005 to 2025: the impact of demographic changes. Iran J Public Health. 2017;46(4):506.PubMedPubMedCentral
8.
go back to reference Aminorroaya A, et al. Burden of non-communicable diseases in Iran: past, present, and future. J Diabet Metabol Disord. 2020. Aminorroaya A, et al. Burden of non-communicable diseases in Iran: past, present, and future. J Diabet Metabol Disord. 2020.
9.
go back to reference Poorhosseini H, Abbasi SH. The Tehran Heart Center. Oxford: Oxford University Press; 2018.CrossRef Poorhosseini H, Abbasi SH. The Tehran Heart Center. Oxford: Oxford University Press; 2018.CrossRef
10.
go back to reference Sarrafzadegan N, Mohammmadifard N. Cardiovascular disease in Iran in the last 40 years: prevalence, mortality, morbidity, challenges and strategies for cardiovascular prevention. Arch Iran Med. 2019;22(4):204–10.PubMed Sarrafzadegan N, Mohammmadifard N. Cardiovascular disease in Iran in the last 40 years: prevalence, mortality, morbidity, challenges and strategies for cardiovascular prevention. Arch Iran Med. 2019;22(4):204–10.PubMed
11.
go back to reference Farzadfar F, et al. National and subnational mortality effects of metabolic risk factors and smoking in Iran: a comparative risk assessment. Popul Health Metrics. 2011;9(1):1–11.CrossRef Farzadfar F, et al. National and subnational mortality effects of metabolic risk factors and smoking in Iran: a comparative risk assessment. Popul Health Metrics. 2011;9(1):1–11.CrossRef
12.
go back to reference Roshandel G, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–83.CrossRef Roshandel G, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–83.CrossRef
13.
go back to reference Salehidoost R, et al. Diabetes and all-cause mortality, a 18-year follow-up study. Sci Rep. 2020;10(1):1–8.CrossRef Salehidoost R, et al. Diabetes and all-cause mortality, a 18-year follow-up study. Sci Rep. 2020;10(1):1–8.CrossRef
14.
go back to reference Sepanlou S, et al. Hypertension and mortality in the golestan cohort study: a prospective study of 50 000 adults in Iran. J Hum Hypertens. 2016;30(4):260–7.CrossRef Sepanlou S, et al. Hypertension and mortality in the golestan cohort study: a prospective study of 50 000 adults in Iran. J Hum Hypertens. 2016;30(4):260–7.CrossRef
15.
go back to reference Fahimfar N, et al. Prediction of cardiovascular disease mortality in a middle eastern country: performance of the Globorisk and score functions in four population-based cohort studies of Iran. Int J Health Policy Manag. 2020. Fahimfar N, et al. Prediction of cardiovascular disease mortality in a middle eastern country: performance of the Globorisk and score functions in four population-based cohort studies of Iran. Int J Health Policy Manag. 2020.
16.
go back to reference Sacco RL, et al. The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation. Circulation. 2016;133(23):e674–90.CrossRef Sacco RL, et al. The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation. Circulation. 2016;133(23):e674–90.CrossRef
17.
go back to reference Sepanlou SG, et al. Levels and trends of hypertension at national and subnational scale in Iran from 1990 to 2016: a systematic review and pooled analysis. Arch Iran Med. 2021; 24(4). Sepanlou SG, et al. Levels and trends of hypertension at national and subnational scale in Iran from 1990 to 2016: a systematic review and pooled analysis. Arch Iran Med. 2021; 24(4).
18.
go back to reference Haghdoust A, Sadeghirad B, Rezazadeh K.M. Epidemiology and heterogeneity of hypertension in Iran: a systematic review. 2008. Haghdoust A, Sadeghirad B, Rezazadeh K.M. Epidemiology and heterogeneity of hypertension in Iran: a systematic review. 2008.
19.
go back to reference Tabatabaei-Malazy O, et al. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. Int J Prev Med. 2014;5(4):373.PubMedPubMedCentral Tabatabaei-Malazy O, et al. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. Int J Prev Med. 2014;5(4):373.PubMedPubMedCentral
20.
go back to reference Federation ID. IDF diabetes atlas ninth. Dunia: IDF; 2019. Federation ID. IDF diabetes atlas ninth. Dunia: IDF; 2019.
22.
go back to reference Reitsma MB, et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021. Reitsma MB, et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021.
23.
go back to reference Bonita R, et al. The WHO stepwise approach to surveillance (STEPS) of non-communicable disease risk factors. In: Global behavioral risk factor surveillance. Springer; 2003. p. 9–22.CrossRef Bonita R, et al. The WHO stepwise approach to surveillance (STEPS) of non-communicable disease risk factors. In: Global behavioral risk factor surveillance. Springer; 2003. p. 9–22.CrossRef
24.
go back to reference Haghdoost AA, et al. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J. 2009;15(3):591–9.CrossRef Haghdoost AA, et al. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J. 2009;15(3):591–9.CrossRef
25.
go back to reference Esteghamati A, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011. Diabetes Res Clin Pract. 2014;103(2):319–27.CrossRef Esteghamati A, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011. Diabetes Res Clin Pract. 2014;103(2):319–27.CrossRef
26.
go back to reference Azadnajafabad S, et al. Non-communicable diseases’ risk factors in Iran; a review of the present status and action plans. J Diabetes Metabol Disord. 2021. Azadnajafabad S, et al. Non-communicable diseases’ risk factors in Iran; a review of the present status and action plans. J Diabetes Metabol Disord. 2021.
27.
go back to reference Fattahi N, et al. Geographical, gender and age inequalities in non-communicable diseases both at national and provincial levels in Iran. J Diabetes Metabol Disord. 2021. Fattahi N, et al. Geographical, gender and age inequalities in non-communicable diseases both at national and provincial levels in Iran. J Diabetes Metabol Disord. 2021.
28.
go back to reference Opoku S, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. 2019;19(1):1500.CrossRef Opoku S, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. 2019;19(1):1500.CrossRef
29.
go back to reference Fishbein MC, Obma R, Roberts WC. Unruptured sinus of Valsalva aneurysm. Am J Cardiol. 1975;35(6):918–22.CrossRef Fishbein MC, Obma R, Roberts WC. Unruptured sinus of Valsalva aneurysm. Am J Cardiol. 1975;35(6):918–22.CrossRef
30.
go back to reference Malekzadeh H, et al. Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007–2016. Sci Rep. 2020;10(1):11724.CrossRef Malekzadeh H, et al. Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007–2016. Sci Rep. 2020;10(1):11724.CrossRef
31.
go back to reference National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. Int J Epidemiol. 2020;49(1):173–192. National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. Int J Epidemiol. 2020;49(1):173–192.
32.
go back to reference Asgari S, et al. The burden of statin therapy based on ACC/AHA and NCEP ATP-III guidelines: an Iranian survey of non-communicable diseases risk factors. Sci Rep. 2018;8(1):4928.CrossRef Asgari S, et al. The burden of statin therapy based on ACC/AHA and NCEP ATP-III guidelines: an Iranian survey of non-communicable diseases risk factors. Sci Rep. 2018;8(1):4928.CrossRef
33.
go back to reference Hamid M, et al. Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007–2016. Sci Rep.2020;10(1). Hamid M, et al. Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007–2016. Sci Rep.2020;10(1).
34.
go back to reference Esteghamati A, et al. Awareness, treatment and control of pre-hypertension and hypertension among adults in Iran. Arch Iran Med. 2016;19(7):456–64.PubMed Esteghamati A, et al. Awareness, treatment and control of pre-hypertension and hypertension among adults in Iran. Arch Iran Med. 2016;19(7):456–64.PubMed
35.
go back to reference Kulsudjarit K. Drug problem in southeast and southwest asia. Ann N Y Acad Sci. 2004;1025:446–57.CrossRef Kulsudjarit K. Drug problem in southeast and southwest asia. Ann N Y Acad Sci. 2004;1025:446–57.CrossRef
36.
go back to reference Nalini M, et al. Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study. Eur J Prev Cardiol. 2021;28(1):98–106.CrossRef Nalini M, et al. Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study. Eur J Prev Cardiol. 2021;28(1):98–106.CrossRef
37.
go back to reference Roayaei P, et al. Opium and cardiovascular health: a devil or an angel? Indian Heart J. 2020;72(6):482–90.CrossRef Roayaei P, et al. Opium and cardiovascular health: a devil or an angel? Indian Heart J. 2020;72(6):482–90.CrossRef
Metadata
Title
Prevalence and trends of coronary artery disease risk factors and their effect on age of diagnosis in patients with established coronary artery disease: Tehran Heart Center (2005–2015)
Authors
Kaveh Hosseini
Seyedeh Hamideh Mortazavi
Saeed Sadeghian
Aryan Ayati
Mahdi Nalini
Arya Aminorroaya
Hamed Tavolinejad
Mojtaba Salarifar
Hamidreza Pourhosseini
Afsaneh Aein
Arash Jalali
Ali Bozorgi
Mehdi Mehrani
Farin Kamangar
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-021-02293-y

Other articles of this Issue 1/2021

BMC Cardiovascular Disorders 1/2021 Go to the issue